WO2016178510A3 - 진세노사이드 Ｆ1 또는 Ｒｇ3를 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물 - Google Patents

진세노사이드 Ｆ1 또는 Ｒｇ3를 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물 Download PDF

Info

Publication number
WO2016178510A3
WO2016178510A3 PCT/KR2016/004699 KR2016004699W WO2016178510A3 WO 2016178510 A3 WO2016178510 A3 WO 2016178510A3 KR 2016004699 W KR2016004699 W KR 2016004699W WO 2016178510 A3 WO2016178510 A3 WO 2016178510A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
gleevec
preventing
leukemia
resistant leukemia
Prior art date
Application number
PCT/KR2016/004699
Other languages
English (en)
French (fr)
Other versions
WO2016178510A2 (ko
Inventor
김선창
김헌식
Original Assignee
재단법인 지능형 바이오 시스템 설계 및 합성 연구단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 filed Critical 재단법인 지능형 바이오 시스템 설계 및 합성 연구단
Priority to EP16789616.6A priority Critical patent/EP3181137A4/en
Priority to US15/511,637 priority patent/US10376530B2/en
Priority to CA2961744A priority patent/CA2961744C/en
Priority to CN201680002797.6A priority patent/CN107073024B/zh
Priority to JP2017514676A priority patent/JP6457074B2/ja
Publication of WO2016178510A2 publication Critical patent/WO2016178510A2/ko
Publication of WO2016178510A3 publication Critical patent/WO2016178510A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

본 발명은 글리벡 내성 백혈병에 대하여 예방 또는 치료효과를 나타내는 진세노사이드 F1 또는 Rg3를 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물, 상기 약학 조성물을 투여하는 단계를 포함하는 글리벡 내성 백혈병의 치료방법 및 글리벡 내성 백혈병 예방 또는 개선용 식품조성물에 관한 것이다. 본 발명의 약학 조성물을 이용하면, 종래의 글리벡에 의해 내성을 나타내는 백혈병을 효과적으로 치료할 수 있으므로, 백혈병의 효과적인 치료에 널리 활용될 수 있을 것이다.
PCT/KR2016/004699 2015-05-06 2016-05-04 진세노사이드 Ｆ1 또는 Ｒｇ3를 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물 WO2016178510A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP16789616.6A EP3181137A4 (en) 2015-05-06 2016-05-04 Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3
US15/511,637 US10376530B2 (en) 2015-05-06 2016-05-04 Pharmaceutical composition for preventing or treating gleevec-resistant leukemia containing ginsenoside F1 or ginsenoside Rg3 as an active ingredient
CA2961744A CA2961744C (en) 2015-05-06 2016-05-04 Pharmaceutical composition for preventing or treating gleevec-resistant leukemia containing ginsenoside f1 or ginsenoside rg3 as an active ingredient
CN201680002797.6A CN107073024B (zh) 2015-05-06 2016-05-04 含人参皂苷f1的用于预防或治疗格列卫耐药性白血病的药学组合物
JP2017514676A JP6457074B2 (ja) 2015-05-06 2016-05-04 ジンセノサイドＦ１またはＲｇ３を有効成分として含むグリベック耐性白血病の予防または治療用薬学組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150063390A KR101733665B1 (ko) 2015-05-06 2015-05-06 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
KR10-2015-0063390 2015-05-06

Publications (2)

Publication Number Publication Date
WO2016178510A2 WO2016178510A2 (ko) 2016-11-10
WO2016178510A3 true WO2016178510A3 (ko) 2016-12-29

Family

ID=57218242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/004699 WO2016178510A2 (ko) 2015-05-06 2016-05-04 진세노사이드 Ｆ1 또는 Ｒｇ3를 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물

Country Status (7)

Country Link
US (1) US10376530B2 (ko)
EP (1) EP3181137A4 (ko)
JP (2) JP6457074B2 (ko)
KR (1) KR101733665B1 (ko)
CN (1) CN107073024B (ko)
CA (1) CA2961744C (ko)
WO (1) WO2016178510A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180000379A (ko) * 2016-06-22 2018-01-03 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 f1을 유효성분으로 포함하는 면역증강용 조성물
KR101948534B1 (ko) * 2017-04-20 2019-02-15 주식회사 이뮤니스바이오 세포밀도 조절을 이용한 자연살해세포의 대량증식방법
CN108904809A (zh) * 2018-08-20 2018-11-30 黎庆有 一种靶向抗肿瘤药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2753372C (en) 2001-06-14 2018-08-07 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
US20060013897A1 (en) * 2002-06-11 2006-01-19 Dong Huang Compositions for cancer therapy saponins or sapogenins
AU2003291896A1 (en) 2002-12-23 2004-07-14 Panagin Pharmaceuticals Inc. Saponins and sapogenins for use in combination therapy for cancer
EP2120978B1 (en) 2006-12-21 2013-11-27 Piramal Enterprises Limited Herbal composition and process for its preparation
EP2152267A2 (en) 2007-06-01 2010-02-17 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
KR20110055833A (ko) 2009-11-20 2011-05-26 건국대학교 산학협력단 플라보노이드를 유효성분으로 하는 백혈병 치료용 조성물
CN102068477B (zh) * 2010-12-31 2012-07-25 浙江省中医院 人参有效部位及其制备方法和应用
CN103570790B (zh) * 2012-08-07 2016-06-01 中国科学院上海药物研究所 原人参二醇衍生物及其制备方法、包含该衍生物的组合物及其用途
KR101483055B1 (ko) 2013-04-26 2015-01-15 초당약품공업 주식회사 백합나무 수피에서 만성 골수성 백혈병 치료 성분을 추출 분리하는 방법

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHOI, C.-H. ET AL.: "Reversal of P-glycoprotein-mediated Multidrug Resistance by Protopanaxatriol Ginsenosides from Korean Red Ginseng", PLANT A MEDICA, vol. 69, no. 3, 2003, pages 235 - 240, XP008029980 *
HASEGAWA, H. ET AL.: "Reveisal of Daunomycin and Vinblastine Resistance in Multidrug-iesistant P388 Leukemia in Vitro through Enhanced Cytotoxicity by Triterpenoids", PLANTA MEDICA, vol. 61, no. 5, 1995, pages 409 - 413, XP001119242 *
HOU, Y. ET AL.: "Ginseng Extract Enhances Anti-cancer Effect of Cytarabine on Human Acute Leukemia Cells", ADVANCE JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, vol. 7, no. 3, 5 February 2015 (2015-02-05), pages 164 - 168, XP009501719 *
KIM, S. -W. ET AL.: "Reversal of P-glycoprotein-mediated Multidrug Resistance by Ginsenoside Rg3", BIOCHEMICAL PHARMACOLOGY, vol. 65, 2003, pages 75 - 82, XP055340547 *
KWON, H.-Y. ET AL.: "Selective Toxicity of Ginsenoside Rg3 on Multidrug Resistant Cells by Membrane Fluidity Modulation", ARCH. PHARM. RES., vol. 31, no. 2, 2008, pages 171 - 177, XP053007308 *
See also references of EP3181137A4 *

Also Published As

Publication number Publication date
EP3181137A4 (en) 2018-02-28
WO2016178510A2 (ko) 2016-11-10
KR101733665B1 (ko) 2017-05-10
CN107073024A (zh) 2017-08-18
JP2019031527A (ja) 2019-02-28
EP3181137A2 (en) 2017-06-21
US20180071327A1 (en) 2018-03-15
CN107073024B (zh) 2020-03-17
KR20160132194A (ko) 2016-11-17
CA2961744C (en) 2019-03-12
JP2017529350A (ja) 2017-10-05
JP6457074B2 (ja) 2019-01-23
CA2961744A1 (en) 2016-11-10
US10376530B2 (en) 2019-08-13

Similar Documents

Publication Publication Date Title
WO2015142001A3 (ko) 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
WO2016142708A3 (en) Pharmaceutical composition
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
WO2012157978A3 (ko) 팥꽃나무 추출물, 이의 분획물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 아토피 예방 또는 치료용 약학적 조성물
EP3266317A4 (en) Composition for preventing, improving or treating neurological disorders, containing osmotin peptide as active ingredient
WO2015058664A8 (zh) 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
EP3336100A4 (en) PEPTIDE WITH EFFECT FOR PREVENTING OR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM THEREFOR AS AN ACTIVE SUBSTANCE
WO2018025080A3 (en) Compositions for enhancing brain activity
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
WO2016178510A3 (ko) 진세노사이드 Ｆ1 또는 Ｒｇ3를 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
WO2016080796A3 (ko) 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도
WO2015126129A3 (ko) C형 간염 바이러스의 게놈 복제의 선택적 저해 활성을 갖는 레스베라트롤 다량체 및 이의 용도
EP3295946A4 (en) Composition, containing lithospermi radix extract as active ingredient, for preventing, alleviating, or treating peripheral neuropathy
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
IL268224A (en) A pharmaceutical compound for the prevention and treatment of pancreatic cancer, containing GOSSYPOL and PHENFORMIN as active ingredients
WO2016109002A3 (en) Methods and compositions for the treatment of radiation-related disorders
EP3260121A4 (en) Composition for preventing, alleviating or treating metabolic diseases, containing amodiaquine as active ingredient
WO2016135456A3 (en) A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy
WO2016093613A3 (ko) 진피 추출물을 포함하는 이상 체중 감소 증상의 예방 또는 치료용 조성물
EP3727397A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT, RELIEF OR PREVENT NEUROPATHIC PAIN, CONTAINING GLYCERYLPHOSPHORYLCHOLINE AS ACTIVE INGREDIENT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16789616

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2017514676

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15511637

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2961744

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2016789616

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2016789616

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE